文献速递前列腺癌

多参数磁共振-超声融合活检提高前列腺癌检出但未取代标准模板活检

Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer.
PubMed 文献 · J Urol · 2019-10-09

该回顾性研究纳入506例接受融合经直肠超声引导前列腺活检的患者,均在同一次操作中先行靶向活检再行标准12针双六分区活检。标准活检与融合活检总体癌检出率为57.7% vs 54.0%(p=0.12),临床显著前列腺癌检出率为24.7% vs 30.8%(p=0.001);若仅行靶向融合活检,185例临床显著前列腺癌中29例(16%)会被漏诊。

要点

  • 融合靶向活检临床显著前列腺癌检出率30.8%高于标准双六分区活检24.7%(p=0.001)。
  • 总体癌检出率标准活检57.7% vs 融合活检54.0%,差异无统计学显著(p=0.12)。
  • 仅行靶向融合活检会漏诊185例中29例(16%)临床显著前列腺癌。

核心结论

  • 融合靶向前列腺活检临床显著前列腺癌检出率高于标准双六分区活检,但标准双六分区活检仍应作为常规融合靶向活检操作的一部分进行,以避免漏诊相当比例的临床显著前列腺癌。

研究设计与样本

  • 回顾性分析前瞻性收集的接受融合经直肠超声引导前列腺活检的患者数据库,共纳入506例。
  • 所有患者在同一次操作中先行靶向活检,随后行标准12针双六分区活检。
  • 所有图像和病灶按前列腺影像报告和数据系统第2版进行分级。
  • 临床显著前列腺癌定义为分级分组2级或以上前列腺癌。

主要发现

  • 活检指征为前列腺特异性抗原升高且既往活检阴性者占46%,主动监测中的前列腺癌者占35%,前列腺特异性抗原升高且无既往活检者占15%,单纯直肠指检异常者占3%。
  • 标准活检与融合活检总体癌检出率为57.7% vs 54.0%(p=0.12)。
  • 标准活检与融合活检临床显著前列腺癌检出率为24.7% vs 30.8%(p=0.001)。
  • 185例诊断为临床显著前列腺癌的患者中,若仅行靶向融合活检,29例(16%)会被漏诊。

关键数值与推荐

  • 临床显著前列腺癌定义为分级分组2级或以上前列腺癌。
  • 标准活检与融合活检总体癌检出率57.7% vs 54.0%(p=0.12)。
  • 标准活检与融合活检临床显著前列腺癌检出率24.7% vs 30.8%(p=0.001)。
  • 仅行靶向融合活检会漏诊185例临床显著前列腺癌中的29例(16%)。

临床怎么用

  • 作者认为,标准双六分区活检仍应作为常规融合靶向前列腺活检操作的一部分进行,以避免漏诊相当比例的临床显著前列腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There exists a growing debate as to whether multiparametric magnetic resonance imaging with fusion transrectal ultrasound guided prostate biopsy alone without a standard template biopsy is sufficient to evaluate patients with suspected prostate cancer. Our objective was to describe our experience with fusion targeted prostate biopsy and assess whether it could obviate the need for concomitant standard 12-core template prostate biopsy. MATERIALS AND METHODS: We retrospectively reviewed our prospectively collected database of patients who underwent fusion transrectal ultrasound guided prostate biopsy. All images and lesions were graded according to the Prostate Imaging Reporting and Data System, version 2. All patients underwent targeted biopsy followed by standard 12-core double sextant biopsy within the same session. Clinically significant prostate cancer was defined as Grade Group 2 or greater prostate cancer. RESULTS: A total of 506 patients were included in analysis. Indications were elevated prostate specific antigen with a previous negative prostate biopsy in 46% of cases, prostate cancer on active surveillance in 35%, elevated prostate specific antigen without a prior prostate biopsy in 15% and an isolated abnormal digital rectal examination in 3%. For standard vs fusion prostate biopsy the overall cancer detection rate was 57.7% vs 54.0% (p=0.12) and the clinically significant prostate cancer detection rate was 24.7% vs 30.8% (p=0.001). Of the 185 patients diagnosed with clinically significant prostate cancer 29 (16%) would have been missed if only targeted fusion prostate biopsy had been performed. CONCLUSIONS: Fusion targeted prostate biopsy is associated with a higher detection rate of clinically significant prostate cancer compared to standard double sextant biopsy. However, standard double sextant biopsy should still be performed as part of the routine fusion targeted prostate biopsy procedure to avoid missing a significant proportion of clinically significant prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Hanna N, Wszolek MF, Mojtahed A, et al. Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer. J Urol. 2019. PMID: 31144593. doi:10.1097/JU.0000000000000359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。